

【学術論文】

- 1) Sugiura I, Doki N, Hata T, Cho R, Ito T, Suehiro Y, Tanaka M, Kako S, Matsuda M, Yokoyama H, Ishikawa Y, Taniguchi Y, Hagihara M, Ozawa Y, Ueda Y, Hirano D, Sakura T, Tsuji M, Kamae T, Fujita H, Hiramoto N, Onoda M, Fujisawa S, Hatta Y, Dobashi N, Nishiwaki S, Atsuta Y, Kobayashi Y, Hayakawa F, Ohtake S, Naoe T, Miyazaki Y. Dasatinib-based 2-step induction for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia. *Blood Adv.* 2022 Jan 25;6(2):624-636.
- 2) 波多智子. 骨髄異形成症候群の薬物治療と血液形態. *日本検査血液学会雑誌* 2022 ; 23(1): 157-165.
- 3) Iida H, Imada K, Ueda Y, Kubo K, Yokota A, Ito Y, Kiguchi T, Hata T, Nawa Y, Ikezoe T, Uchida T, Morita Y, Kawashima I, Chiba M, Morimoto K, Hirooka S, Miyazaki Y, Ohno R, Naoe T. A phase II randomized study evaluating azacitidine versus conventional care regimens in newly diagnosed elderly Japanese patients with unfavorable acute myeloid leukemia. *Int J Hematol.* 2022 May;115(5):694-703.
- 4) Miyazaki Y, Kiguchi T, Sato S, Usuki K, Ishiyama K, Ito Y, Suzuki T, Taguchi J, Chiba S, Dobashi N, Tomita A, Harada H, Handa H, Horiike S, Maeda T, Matsuda M, Ichikawa M, Hata T, Honda S, Iyama S, Suzushima H, Moriuchi Y, Kurokawa T, Yokota K, Ohtake S, Yamauchi T, Matsumura I, Kiyoi H, Naoe T. Japan Adult Leukemia Study Group. Prospective comparison of 5- and 7-day administration of azacitidine for myelodysplastic syndromes: a JALSG MDS212 trial. *Int J Hematol.* 2022 Aug;116(2):228-238.
- 5) 古本嵩文、牧山純也、鳥山愛生、新野大介、波多智子、森内幸美、宮崎泰司. 移植後 cyclophosphamide を用いた HLA 半合致移植を施行した骨髄肉腫合併骨髄異形成症候群. *臨床血液* 2022;63(5):341-346.
- 6) Morita Y, Nannya Y, Ichikawa M, Hanamoto H, Shibayama H, Maeda Y, Hata T, Miyamoto T, Kawabata H, Takeuchi K, Tanaka H, Kishimoto J, Miyano S, Matsumura I, Ogawa S, Akashi K, Kanakura Y, Mitani K. ASXL1 mutations with serum EPO levels predict poor response to darbepoetin alfa in lower-risk MDS: W-JHS MDS01 trial. *Int J Hematol.* 2022 Nov;116(5):659-668.

- 7) Sakamoto H, Ando K, Imaizumi Y, Mishima H, Kinoshita A, Kobayashi Y, Kitanosono H, Kato T, Sawayama Y, Sato S, Hata T, Nakashima M, Yoshiura KI, Miyazaki Y. Alvocidib inhibits IRF4 expression via super-enhancer suppression and adult T-cell leukemia/lymphoma cell growth. *Cancer Sci.* 2022 Dec;113(12):4092-4103.
- 8) 奈良谷俊、水下彩子、木下和久、田倉雅之、吉野恭平、坂本一郎、入江準二、栗山一孝. 開心術後に発生した胆嚢出血の1例. *超音波検査技術* 2022; 47(2): 138-145.